Pharmaceutical company compliance officers support having board members certify compliance programs but would like more flexibility in monitoring corporate activities and in the reviews conducted by independent review organizations.
These are some of the findings that came out of a government-industry pharmaceutical compliance roundtable discussion that HHS’ Office of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?